@article{10.37349/emed.2025.1001269,
abstract = {Aim: This study aimed to explore the feasibility and preliminary efficacy of cinobufacini in patients with oral premalignant lesions (OPLs). Methods: Patients with histologically confirmed OPLs participated in an open-label uncontrolled pilot clinical study and received a 4-week or 12-week treatment, the efficacy and safety of cinobufacini for the treatment of OPLs were assessed. Results: During the treatment course ranging from 4 weeks to 12 weeks, no one withdrew because of adverse effects, no one had clinical or histologic progressive disease. Of the 8 participants who took cinobufacini for 12 weeks, one had a complete clinical response, and 4 had a complete histologic response. Of note, 9 participants had varying degrees of pain reduction. Conclusions: This small pilot study supports the feasibility of a larger clinical trial to evaluate the efficacy of cinobufacini in the treatment of OPLs [Chinese Clinical Trial Registry (chictr.org.cn) identifier: ChiCTR2300068529].},
author = {Liu, Yang and Huang, Ping and Ming, Jie and Wang, Yuhong and Wang, Yuanyuan and Wei, Minghui and Cui, Yuan and Wei, Jiao and Wang, Xinwen},
doi = {10.37349/emed.2025.1001269},
journal = {Exploration of Medicine},
elocation-id = {1001269},
title = {Feasibility of cinobufacini for the treatment of oral premalignant lesions: an open-label pilot trial},
url = {https://www.explorationpub.com/Journals/em/Article/1001269},
volume = {6},
year = {2025}
}